Sports Medicine and Health Science(SMHS)has a short but impressive history.Following two diligent years of preplanning,SMHS was founded in 2019 by Co-Editors-in-Chief Dr.J.Larry Durstine and Dr.Quansheng Su.Dr.J.Larry...Sports Medicine and Health Science(SMHS)has a short but impressive history.Following two diligent years of preplanning,SMHS was founded in 2019 by Co-Editors-in-Chief Dr.J.Larry Durstine and Dr.Quansheng Su.Dr.J.Larry Durstine is retiring from his position on December 31,2025 and I am honored to accept the role of Editor-in-Chief(EIC)of SMHS along with Dr.Su.I want to begin my term as EIC by thanking Dr.J.Larry Durstine for his hard work and excellent editorial leadership during the first six years of journal operation.My job as the new EIC of SMHS will be to build on the already established excellence of the journal.展开更多
Submacular haemorrhage(SMH)is a sight threatening complication that can occur in exudative age related macular degeneration(AMD),but has been described to occur more frequently in eyes with polypoidal choroidal vascul...Submacular haemorrhage(SMH)is a sight threatening complication that can occur in exudative age related macular degeneration(AMD),but has been described to occur more frequently in eyes with polypoidal choroidal vasculopathy(PCV).Left untreated,SMH carries a grave visual prognosis.Thus,expedient diagnosis and effective management of this complication is of paramount importance.The treatment strategies for SMH include(I)displacement of blood from the fovea,usually by injection of an expansile gas;(II)pharmacologic clot lysis such as with recombinant tissue plasminogen activator(rtPA);and(III)treatment of the underlying choroidal neovascularization(CNV)or PCV,such as with anti-vascular endothelial growth factor(anti-VEGF)agents.These three strategies have been employed in isolation or in combination,some concurrently and others in stages.rtPA has demonstrable effect on the liquefaction of submacular clots but there are remaining uncertainties with regards to the dose,safety and the timing of initial and repeat treatments.Potential side effects of rtPA include retinal pigment epithelial toxicity,increased risk of breakthrough vitreous haemorrhage and systemic toxicity.In cases presenting early,pneumatic displacement alone with anti-VEGF may be sufficient.Anti-VEGF monotherapy is a viable treatment option particularly in patients with thinner SMH and those who are unable to posture post pneumatic displacement.展开更多
文摘Sports Medicine and Health Science(SMHS)has a short but impressive history.Following two diligent years of preplanning,SMHS was founded in 2019 by Co-Editors-in-Chief Dr.J.Larry Durstine and Dr.Quansheng Su.Dr.J.Larry Durstine is retiring from his position on December 31,2025 and I am honored to accept the role of Editor-in-Chief(EIC)of SMHS along with Dr.Su.I want to begin my term as EIC by thanking Dr.J.Larry Durstine for his hard work and excellent editorial leadership during the first six years of journal operation.My job as the new EIC of SMHS will be to build on the already established excellence of the journal.
文摘Submacular haemorrhage(SMH)is a sight threatening complication that can occur in exudative age related macular degeneration(AMD),but has been described to occur more frequently in eyes with polypoidal choroidal vasculopathy(PCV).Left untreated,SMH carries a grave visual prognosis.Thus,expedient diagnosis and effective management of this complication is of paramount importance.The treatment strategies for SMH include(I)displacement of blood from the fovea,usually by injection of an expansile gas;(II)pharmacologic clot lysis such as with recombinant tissue plasminogen activator(rtPA);and(III)treatment of the underlying choroidal neovascularization(CNV)or PCV,such as with anti-vascular endothelial growth factor(anti-VEGF)agents.These three strategies have been employed in isolation or in combination,some concurrently and others in stages.rtPA has demonstrable effect on the liquefaction of submacular clots but there are remaining uncertainties with regards to the dose,safety and the timing of initial and repeat treatments.Potential side effects of rtPA include retinal pigment epithelial toxicity,increased risk of breakthrough vitreous haemorrhage and systemic toxicity.In cases presenting early,pneumatic displacement alone with anti-VEGF may be sufficient.Anti-VEGF monotherapy is a viable treatment option particularly in patients with thinner SMH and those who are unable to posture post pneumatic displacement.
